Navigation Links
Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
Date:9/10/2007

BERKELEY HEIGHTS, N.J. and RALEIGH, N.C., Sept. 10 /PRNewswire/ -- Clinsys Clinical Research, Inc., a therapeutically focused clinical research organization, today announced the appointments of Rajagopalan Srinivasan, Ph.D as Vice President, Global Biostatistics and Christopher Gregory, Ph.D as Scientific Affairs-Director.

"I am excited to have Drs. Srinivasan and Gregory, both highly experienced professionals in their respective fields in clinical research, join the Clinsys team," said David E. Williams, Chief Executive Officer of Clinsys Clinical Research. Mr. Williams continues, "Dr. Srinivasan, who will head up our global biostatistics service offering, brings substantial expertise in biostatistics directly relating to our key therapeutic areas of Oncology, Cardiovascular and CNS. Dr. Gregory, who will serve as a senior scientific advisor for our clinical project teams, brings a wealth of direct pharmaceutical research development and academic experience to support our global regulatory and scientific affairs services."

Dr. Srinivasan has over 25 years of experience in biostatistics with regulated drug industry and medical research, including 10 years working at the FDA. He has held a number of senior management positions in the drug development industry, most recently as Vice President, Global Biostatistics with a global clinical research organization. During his tenure at the FDA, Dr. Srinivasan provided statistical guidance to regulated industry in each step of drug development (Pre-IND, IND, End of Phase II, pre-NDA, NDA as well as post-marketing Phase IV commitments). Dr. Srinivasan has taught Biostatistics/Statistics at the George Washington University, Washington, DC and is currently an adjunct Professor of Biostatistics at University of Virginia, Charlottesville, Virginia. He received his B. Sc. (Honors), M.A. and M. Phil degrees in Statistics from the University of Madras in India, his Masters in Biostatistics from Florida State Unive
'/>"/>

SOURCE Clinsys Clinical Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. What patients want: A story of choice, clinical trials & evidence-based medicine
3. ZyStor seeks to raise $15M for clinical trials
4. Prodesse begins clinical trials for flu virus detection
5. ConjuGon raises $3.3 million to fund clinical trials
6. Cancer-fighting agent heads for clinical trials
7. Quintessence cancer treatment chosen for clinical studies
8. Third Wave reports clinical growth, continued loss
9. Childrens expanding use of Sunrise Clinical Manager
10. Life-sciences conference to feature novel research with clinical potential
11. $14 million grant to drive clinical research at UW

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)..., OMAHA, Neb., Nov. 5 T... announced financial results for the quarter ended...ts are presented in the tables that follow. ,, ...net loss of $366,000 or $0.01 per share for the th...499,000 or $0.01 per share for the third quarter o...
(Date:11/5/2009)..., FREMONT, Calif., Nov. 5 /PRNewswire-FirstCall/ ...WGBS), a leading developer of state-of-the-art gen...opher Sears, Ph.D. has joined the company,s Scient...on designing and commercializing novel molecular d...ions, and on the development of computational biol...
(Date:11/5/2009)... Brooke Sanders brings a new...ne, CA (PRWEB) November 5, 2009 -- Professional Re... reprographics company is pleased to present Brook... as their graphics/PR specialist. The addition of ...sistent growth within Professional Reprographics.,...
(Date:11/4/2009)..., ,, ROCKVILLE, Md., Nov. 4 /PRNewswire/ -... company focused on next-generation antibody drug ...10 million in Series A funding from New Enterprise...ure capital firms. The capital will be used to cre...that address two or more biological targets with a...
Breaking Biology Technology:Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
...y insiders knowingly misrepresented the .... 18 Hagens Berman Sobol Shapiro filed a,proposed...cs Corporation,(OTC Bulletin Board: CCYG) sharehol...esented the company and chief executive officer Ga...be traded at artificially,inflated prices., The l...
... and Company,strongly objects to implications in a...e company has suppressed results of negative clini...le in The New England Journal of,Medicine (NEJM), ... how the,industry purportedly suppresses negative ... inaccurate when it comes to Prozac -- the NEJM ar...
...utics Corporation today,announced the appointment ...Alliance Management. In this role, Ms. Perrow will...opment strategy and program execution through,prod...l also serve as a,member of Alba,s executive manag...nnounce that Ms. Perrow is joining Alba in,this cr...
Other Biology Technology:Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management 2
(Date:11/4/2009)...D, Calif., Oct. 23 GenVault Corpor... management for genomic discovery, medicine and id...h.D., GenVault,s President and CEO, will be presen...e on October 26th and 27th in La Jolla, CA. ,, ...n overview of the company together with recent cus...
(Date:11/4/2009)...K, Oct. 27 Global Rainmakers, Inc....anced R&D laboratory, today announced that the...ared to actively commercialize its suite of techno... security offerings. ,, During the past four ye...lars to develop and deploy a series of core--but e...
(Date:11/4/2009)...D, Calif., Nov. 4 GenVault Corpora...rody, M.D., Ph.D., has joined its Board of Directo...r of the Salk Institute, is an acclaimed physician...g the Salk Institute, Dr. Brody served as presiden... of the National Academy of Engineering and the In...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Martin Hensen head of e strategies UCB Germany 3A Making e marketing more than just an add on 9458 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 2Five Questions About Protopic 28tacrolimus 29 Ointment 13332 3Five Questions About Protopic 28tacrolimus 29 Ointment 13332 4Synthetic biology opportunities and risks 53488 1Synthetic biology opportunities and risks 53488 2Synthetic biology opportunities and risks 53488 3
...ed to exploring ways to broaden the use of clean, ...y 1 at Stanford University. , Energy Crossroads, ...ms to reduce society,s dependence on fossil fuels,...ion: Sparking Global Change." , Cathy Zoi, chief ...ection, a nonprofit organization founded by former...
...gist Stephan B. Poulter demonstrates in THE MOTHER... YOUR LIFE (Prometheus Books, $18.95) that most of...ted by our mothers or its far-reaching impact on o... the foundation from which our emotional developme...ve through adulthood. No other relationship in ou...
...ollaborative effort, researchers from Boston Unive...at deletions or mutations within the TFAP2A gene (... distinctive clefting disorder Branchio-Oculo-Faci...erized by specific skin anomalies involving the ne...l facial appearance, and frequently cleft lip and ...
Other Biology News:How your mother's emotional legacy impacts your life 2
Sheep Anti-Human Factor XIII Antibody, Horseradish Peroxidase Conjugated from CEDARLANE Laboratories Limited
Immunoblot Blocking Reagent from Upstate
Rabbit Anti-DAP12 Polyclonal Antibody, Unconjugated from Exalpha Biologicals, Inc.
Amido Black 10B, CI 20470 from Research Organics, Inc.
Biology Products: